{"id":"NCT01704651","sponsor":"Jamie N. Bakkum-Gamez","briefTitle":"Accelerating Gastrointestinal Recovery","officialTitle":"Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2015-08","completion":"2015-10","firstPosted":"2012-10-11","resultsPosted":"2016-10-24","lastUpdate":"2016-10-24"},"enrollment":146,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer"],"interventions":[{"type":"DRUG","name":"Alvimopan","otherNames":["Entereg"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Alvimopan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian cancer.","primaryOutcome":{"measure":"Postoperative Length of Hospital Stay","timeFrame":"Patients will be followed for the duration of their hospital stay, an expected average of 5 days","effectByArm":[{"arm":"Alvimopan","deltaMin":4.4,"sd":2.7},{"arm":"Placebo","deltaMin":4.3,"sd":2.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.34"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":66},"commonTop":["Anemia","Constipation","Nausea","Ileus","Vomiting"]}}